Obe-cel was designed to increase T-cell persistence and reduce T-cell exhaustion and was shown to improve response rates and survival, particularly in patients with low leukemia burden.

Highlights in myasthenia gravis from AANEM 2024 include efficacy data on efgartigimod, ravulizumab, zilucoplan, and first-in-class inebilizumab, as well as safety outcomes in pregnancy for eculizumab.

A retrospective cohort study using data from patients in 21 countries showed use of semaglutide use was not linked to an ...

Researchers looked for associations of plasma omega-3 and omega-6 polyunsaturated fatty acids with the incidence of cancer.

Increased demands from an aging population and pandemic-related supply shortages leave provinces scrambling to allocate ...

Patients with celiac disease who take an angiotensin receptor blocker (ARB) may experience worse outcomes, such as iron ...

A series of botulism cases in Italy and France have raised concerns about food safety. What can people do to avoid the deadly ...

The US Food and Drug Administration (FDA) sometimes allows cancer drugs with accelerated approvals to remain on the market ...

First, there were “Ozempic babies.” Now, there is also Ozempic-before-baby. Unplanned pregnancies are still regularly being ...

A disease historically associated with malnourishment on sailing vessels may have a new, modern culprit: Bariatric surgery.

US endocrinologists are favoring antithyroid drugs over radioactive iodine in initial Graves’ disease treatment, and new ...

SAN ANTONIO — Several types of anti-obesity medications (AOMs), including glucagon-like peptide 1s (GLP-1s), are associated ...